Loading...
Please wait, while we are loading the content...
Similar Documents
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
| Content Provider | Semantic Scholar |
|---|---|
| Author | Fruehauf, Stefan Otremba, Burkhard Joerg Rudolph, Christine |
| Copyright Year | 2016 |
| Abstract | INTRODUCTION Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NCT01627990) was to observe the tolerability, safety and efficacy of biosimilar filgrastim in patients receiving cancer chemotherapy. METHODS This was a prospective, multicenter, non-interventional, longitudinal study. Consenting adult patients with solid tumors or hematologic malignancies for whom cytotoxic chemotherapy and treatment with biosimilar filgrastim was planned were enrolled. RESULTS Among the enrolled patients (N = 386), 81% were female, with a median age (range) of 61 (22-92) years, with 39% >65 years old. Most patients (n = 338; 88%) had solid tumors and the remainder (n = 49; 13%) had hematological malignancies. The majority of the patients (64%) received biosimilar filgrastim as primary prophylaxis and 36% as secondary prophylaxis. At the follow-up visits, for the majority of patients (95.6%) there had been no change in chemotherapy dose due to FN. For two patients (0.5%) the chemotherapy was discontinued due to FN and for four patients (1.0%) the chemotherapy dose was reduced due to FN. For the majority of patients (96.9%) the chemotherapy cycle following the first biosimilar filgrastim treatment was not delayed due to FN. For 3 patients (0.8%), the chemotherapy was delayed following the first biosimilar filgrastim treatment. Less than one-third (29.8%) of the patients experienced ≥1 adverse event that was at least potentially related to biosimilar filgrastim treatment. CONCLUSIONS Biosimilar filgrastim was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing chemotherapy for solid tumors and hematological malignancies. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT01627990. FUNDING Hospira Inc, A Pfizer Company, Lake Forest, IL, USA. |
| Starting Page | 1983 |
| Ending Page | 2000 |
| Page Count | 18 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://rd.springer.com/content/pdf/10.1007/s12325-016-0419-1.pdf |
| PubMed reference number | 27743353 |
| Volume Number | 33 |
| Journal | Advances in therapy |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | 0.5 ML Tbo-filgrastim 0.6 MG/ML Prefilled Syringe Adverse event Antineoplastic Chemotherapy Protocols Colony-Stimulating Factors Condoms, Unspecified Cytotoxic Chemotherapy Febrile Neutropenia Fever Filgrastim Forty Nine Hematologic Neoplasms Hematology (discipline) Malignant Childhood Central Nervous System Neoplasm Neoplasms, Unknown Primary Patients Supportive care granulocyte solid tumor |
| Content Type | Text |
| Resource Type | Article |
